Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement

Copenhagen, Denmark; November 11, 2015 – Genmab A/S (OMX: GEN) will increase its share capital by 209,133 shares as a consequence of the exercise of employee warrants.

The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1:

• 3,713 shares at DKK 31.75,
• 50,000 shares at DKK 40.41,
• 2,250 shares at DKK 55.85,
• 1,000 shares at DKK 66.60,
• 4,750 shares at DKK 67.50,
• 250 shares at DKK 68.65,
• 2,125 shares at DKK 79.25,
• 500 shares at DKK 80.55,
• 1,750 shares at DKK 129.75,
• 5,000 shares at DKK 173,
• 1,131 shares at DKK 184,
• 5,000 shares at DKK 210.50,
• 7,000 shares at DKK 220.40,
• 812 shares at DKK 224,
• 1,000 shares at DKK 225.30,
• 1,000 shares at DKK 225.90,
• 2,000 shares at DKK 231.50,
• 500 shares at DKK 234,
• 4,500 shares at DKK 234.75,
• 3,400 shares at DKK 246,
• 32,750 shares at DKK 254,
• 12,625 shares at DKK 272,
• 1,862 shares at DKK 326.50,
• 3,900 shares at DKK 329,
• 2,588 shares at DKK 330,
• 44,815 shares at DKK 352.50, and
• 12,912 shares at DKK 364.

Proceeds to the company are approximately DKK 44.9 million. The increase corresponds to approx. 0.4 % of the company's share capital.

The increase includes the exercise of 50,000 warrants by President & CEO Jan van de Winkel.

The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription, i.e. inter alia full rights to dividends for the financial year 2015. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. Genmab A/S' current share capital amounts to DKK 59,322,130 and will after the capital increase be DKK 59,531,263. The capital increase is expected to be finalized shortly.

About Genmab
Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company currently has one marketed antibody, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and daratumumab in clinical development for multiple myeloma and non-Hodgkin’s lymphoma, in addition to other clinical programs, and an innovative pre-clinical pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          
Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab^®; the Y-shaped Genmab logo^®; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo^®; the HexaBody logo™; HuMax^®; HuMax-CD20^®; DuoBody^®; HexaBody^® and UniBody^®. Arzerra^® is a trademark of Novartis AG or its affiliates.

Company Announcement no. 54
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark

Vedhæftede filer:

54_warrant exercise_111115_uk.pdf